ČESKÁ UROLOGIE / CZECH UROLOGY – 4 / 2019

323 ORIGINÁLNÍ PRÁCE Ces Urol 2019; 23(4): 316–324 LITERATURA 1. Zowawi HM, Harris PN, Roberts MJ, et al. The emerging threat of multidrug‑resistant Gram‑negative bacteria in urology. Nat Rev Urol. 2015; 12(10): 570–584. 2. Bonkat G, Pickard R, Bartoletti R, et al. EAU Guidelines on Urological Infections. European Association of Urology. 2017. 3. Le Fanu J. The Rise and Fall of Modern Medicine. Hachette, Londýn 2011; 13–20. ISBN 978-0-349-12375-2. 4. Bonkat G, Müller G, Braissant O, et al. Increasing prevalence of ciprofloxacin resistance in extended‑spectrum‑β-lactamase‑producing Escherichia coli urinary isolates. World J Urol. 2013; 31(6): 1427–1432. 5. Fajfr M, Louda M, Paterová P, et al. The susceptibility to fosfomycin of Gram‑negative bacteria isolates from urinary tract infection in the Czech Republic: data from a unicentric study. BMC Urol. 2017; 26; 17(1): 33. 6. Magyar A, Köves B, Nagy K, et al. Spectrum and antibiotic resistance of uropathogens between 2004 and 2015 in a tertiary care hospital in Hungary. J Med Microbiol. 2017; 66(6): 788–797. 7. Toner L, Papa N, Aliyu SH, et al. Extended‑spectrum beta‑lactamase‑producing Enterobacteriaceae in hospital urinary tract infections: incidence and antibiotic susceptibility profile over 9 years. World J Urol. 2016; 34(7): 1031–1037. 8. Sbiti M, Lahmadi K, Louzi L. Epidemiological profile of uropathogenic enterobacteria producing ex‑ tended spectrum beta‑lactamases]. Pan Afr Med J. 2017; 13: 28–29. 9. Girometti N, Lewis RE, Giannella M, et al. Klebsiella pneumoniae bloodstream infection: epidemiology and impact of inappropriate empirical therapy. Medicine (Baltimore) 2014; 93(17): 298–309. 10. Cho YH, Jung SI, Chung HS, et al. Antimicrobial susceptibilities of extended‑spectrum beta‑lactamase‑producing Escherichia coli and Klebsiella pneumoniae in health care‑associated urinary tract infection: focus on susceptibility to fosfomycin. Int Urol Nephrol. 2015; 47(7): 1059–1066. 11. Concia E, Azzini AM. Aetiology and antibiotic resistance issues regarding urological procedures. J Chemother. 2014; 26Suppl 1: S14–23. 12. ValléeM, Bruyère F, Roblot F, Brureau L. Temocillin and urinary tract infections. ProgUrol. 2017; 27(12): 609–617. 13. Wagenlehner FM, Alidjanov JF. Efficacy, pharmacokinetic and pharmacodynamics profile of ceftolozane + tazobactam in the treatment of complicated urinary tract infections. Expert Opin Drug MetabToxicol. 2016; 12(8): 959–966. 14. Stapleton PJ, Lundon DJ, McWade R, et al. Antibiotic resistance patterns of Escherichia coli urinary isolates and comparison with antibiotic consumption data over 10 years, 2005–2014. Ir J Med Sci. 2017; 186(3): 733–741. 15. Jiménez‑Alcaide E, Medina‑Polo J, García‑González L, et al. Healthcare‑associated urinary tract infections in patients with a urinary catheter: Risk factors, microbiological characteristics and patterns of antibiotic resistance]. Arch Esp Urol. 2015; 68(6): 541–550. 16. Černohorská L, Sláviková P. Pseudomonas aeruginosa, její rezistence k vybraným antibiotikům a tvorba biofilmu u kmenů izolovaných od pacientůs infekcí močových cest. Epidemiol Mikrobiol Imunol. 2009; 58(4): 154–157. 17. Toner L, Papa N, Aliyu SH, et al. Vancomycin resistant enterococci in urine cultures: Antibiotic susceptibi‑ lity trends over a decade at a tertiary hospital in the United Kingdom. Investig Clin Urol. 2016; 57(2): 129–134. 18. Lara‑Isla A, Medina‑Polo J, Alonso‑Isa M, et al. Urinary Infections in Patients with Catheters in the Upper Urinary Tract: Microbiological Study. Urol Int. 2017; 98(4): 442–448. 19. Cai T, Mazzoli S, Lanzafame P et al. Asymptomatic bacteriuria in Clinical Urological Practice: Preo‑ perative Control of Bacteriuria and Management of Recurrent UTI. Pathogens 2016; 5: 4. doi: 10.3390/ pathogens5010004. 20. Routh JC, Alt AL, Ashley RA, Kramer SA, Boyce TG. Increasing prevalence and associated risk factors for methicillin resistant Staphylococcus aureus bacteriuria. J Urol. 2009; 181(4): 1694–1698.